AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

The positive trial results have not only demonstrated rosnilimab's potential in treating RA but have also validated AnaptysBio's scientific approach in targeting PD-1 co-inhibitory receptors on ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...